Vitrolife AB Announces Executive Appointments, Effective January 1, 2022
December 01, 2021 at 07:00 am EST
Share
Vitrolife AB (publ) completed the acquisition of Igenomix, as a result, changes will be made to the executive management team effective 1 January, 2022. The executive management team will from 1 January, 2022, consist of: Group Functions: Francisco Jim?nez, SVP Strategy & Corporate Development, Karin Koritz Russberg, SVP HR & Sustainability, Carlos Sim?n, Chief Scientific Officer; Business Areas: Claus Bisgaard, SVP Vitrolife Technology, Ricardo Capella, SVP Igenomix, Maria Forss, SVP Vitrolife Consumables and Business Functions: Rickard Ericsson, SVP Vitrolife Sales & Marketing and Francisco Rodriguez, SVP Igenomix Affiliates.
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Companyâs product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
VITROLIFE AB 
